Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 77,248	$ 130,101
Marketable securities, short-term	67,633	47,504
Prepaid expenses and other current assets	4,657	2,724
Total current assets	149,538	180,329
Marketable securities, long-term	27,311	15,837
Property and equipment, net	136	165
Deferred offering costs	183	0
Right-of-use asset	29	105
Other assets	208	151
Total assets	177,405	196,587
Current liabilities
Accounts payable	2,026	1,640
Accrued clinical trial expenses	4,102	2,717
Accrued expenses and other current liabilities	2,374	3,350
Operating lease liability	29	105
Total current liabilities	8,531	7,812
Total liabilities	8,531	7,812
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized and 41,025,062 shares issued and outstanding as of June 30, 2023 and December 31, 2022	4	4
Additional paid-in capital	362,860	359,949
Accumulated deficit	(193,344)	(170,427)
Accumulated other comprehensive loss	(646)	(751)
Total stockholders’ equity	168,874	188,775
Total liabilities and stockholders’ equity	$ 177,405	$ 196,587